Camrelizumab
Pharmaceutical drug
- none
- 1798286-48-2
- 73096E137E
Camrelizumab (SHR-1210) (INN[1]) is an anti-PD-1 immune checkpoint inhibitor that is being investigated for hepatocellular carcinoma and Hodgkin lymphoma.[2]
This drug is being developed by Jiangsu HengRui Medicine Co., Ltd. As of 2019[update], camrelizumab is undergoing Phase II/III trials.
References
- ^ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 77" (PDF). WHO Drug Information. 31 (1).
- ^ Nie J, Wang C, Liu Y, Yang Q, Mei Q, Dong L, et al. (June 2019). "Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma". Journal of Clinical Oncology. 37 (17): 1479–1489. doi:10.1200/JCO.18.02151. PMID 31039052. S2CID 141482897.
- v
- t
- e
Monoclonal antibodies for the immune system
Human | |
---|---|
Humanized | |
Veterinary |
Mouse |
|
---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e